These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38510235)

  • 1. TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.
    Cianciotti BC; Magnani ZI; Ugolini A; Camisa B; Merelli I; Vavassori V; Potenza A; Imparato A; Manfredi F; Abbati D; Perani L; Spinelli A; Shifrut E; Ciceri F; Vago L; Di Micco R; Naldini L; Genovese P; Ruggiero E; Bonini C
    Front Immunol; 2024; 15():1315283. PubMed ID: 38510235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion.
    Teagle AR; Castro-Sanchez P; Brownlie RJ; Logan N; Kapoor SS; Wright D; Salmond RJ; Zamoyska R
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
    Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
    Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
    Fourcade J; Sun Z; Benallaoua M; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Kuchroo V; Zarour HM
    J Exp Med; 2010 Sep; 207(10):2175-86. PubMed ID: 20819923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor antigen-specific CD8
    Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
    Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rare population of tumor antigen-specific CD4
    Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
    J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment.
    Yang M; Du W; Yi L; Wu S; He C; Zhai W; Yue C; Sun R; Menk AV; Delgoffe GM; Jiang J; Lu B
    Oncoimmunology; 2020; 9(1):1708064. PubMed ID: 32076578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
    Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
    J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased co-expression of TIM-3 with TIGIT or 2B4 on CD8+ T cells is associated with poor prognosis in locally advanced nasopharyngeal carcinoma.
    Xie X; Feng Y; Fan P; Dong D; Yao X; Peng Y; Wang R
    Biomol Biomed; 2023 Jul; 23(4):584-595. PubMed ID: 36913701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease.
    Mastaglio S; Genovese P; Magnani Z; Ruggiero E; Landoni E; Camisa B; Schiroli G; Provasi E; Lombardo A; Reik A; Cieri N; Rocchi M; Oliveira G; Escobar G; Casucci M; Gentner B; Spinelli A; Mondino A; Bondanza A; Vago L; Ponzoni M; Ciceri F; Holmes MC; Naldini L; Bonini C
    Blood; 2017 Aug; 130(5):606-618. PubMed ID: 28637663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells.
    Sullivan PM; Reed SJ; Kalia V; Sarkar S
    Front Immunol; 2021; 12():706150. PubMed ID: 34867942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
    Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
    Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
    Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U
    Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion.
    Ferris RL; Lu B; Kane LP
    J Immunol; 2014 Aug; 193(4):1525-30. PubMed ID: 25086175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
    Fourcade J; Sun Z; Pagliano O; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Olive D; Kuchroo V; Zarour HM
    Cancer Res; 2012 Feb; 72(4):887-96. PubMed ID: 22205715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome.
    Ciraolo E; Althoff S; Ruß J; Rosnev S; Butze M; Pühl M; Frentsch M; Bullinger L; Na IK
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
    Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
    Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.